捐赠卵母细胞体外受精预测模型的开发:基于10 877个胚胎移植周期的回顾性分析
本研究利用澳大利亚临床登记数据9384个胚胎移植周期开发预测模型,并在新西兰1493个周期中进行外部验证,预测使用捐赠卵母细胞形成的胚胎移植后活产几率。最佳模型内部验证AUC-ROC为0.60、Brier分数为0.20,外部验证AUC-ROC为0.61、Brier分数为0.23,模型校准良好且具有泛化能力,但区分度相对较弱。
要点
- 最佳模型内部验证AUC-ROC为0.60、外部验证AUC-ROC为0.61,区分度相对较弱。
- 预测活产最重要的变量为卵母细胞捐赠者年龄、既往接受者胚胎移植周期数、胚胎卵裂期或囊胚期及接受者年龄。
- 所开发模型之一已纳入面向消费者的网站,供患者获取使用捐赠卵母细胞的个性化成功几率估计。
核心结论
- 利用澳大利亚数据开发了三个包含患者、既往治疗和周期特征的预测模型,用于预测使用捐赠卵母细胞形成的胚胎移植后活产几率。
- 这些模型对研究人群校准良好,在测试新西兰数据时达到合理的预测能力和泛化能力。
研究设计与样本
- 本研究使用基于澳大利亚人群的临床登记数据,包含2015年至2021年间发生的9384个胚胎移植周期用于模型开发,外部验证队列为1493个新西兰胚胎移植周期。
主要发现
- 最佳模型的内部验证AUC-ROC为0.60、Brier分数为0.20,外部验证AUC-ROC为0.61、Brier分数为0.23。
- 与在同一人群的自体队列中评估的模型相比,这些结果提示区分能力约低15%。
- 模型的性能在统计学上显著优于随机,表现出泛化能力,并对研究人群校准良好。
- 预测活产几率最重要的变量为卵母细胞捐赠者年龄、既往卵母细胞接受者胚胎移植周期数、移植胚胎为卵裂期或囊胚期以及卵母细胞接受者年龄。
- 较不重要的变量为卵母细胞接受者的产次、使用捐赠者或伴侣精子、既往自体胚胎移植周期数以及移植胚胎数。
临床怎么用
- 所开发模型之一已纳入面向消费者的网站(YourIVFSuccess.com.au/Estimator),使患者能够获得使用捐赠卵母细胞的个性化成功几率估计。
局限性
- 模型区分度相对较弱,提示需要添加进一步特征以提高预测能力。
- 各国捐赠卵母细胞队列存在差异,例如是否允许匿名和补偿捐赠,可能需要在非澳大利亚队列应用前重新校准模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can we develop a prediction model for the chance of a live birth following the transfer of an embryo created using donated oocytes? SUMMARY ANSWER: Three primary models that included patient, past treatment, and cycle characteristics were developed using Australian data to predict the chance of a live birth following the transfer of an embryo created using donated oocytes; these models were well-calibrated to the population studied, achieved reasonable predictive power and generalizability when tested on New Zealand data. WHAT IS KNOWN ALREADY: Nearly 9% of ART embryo transfer cycles performed globally use embryos created using donated oocytes. This percentage rises to one-quarter and one-half in same-sex couples and women aged over 45 years, respectively. STUDY DESIGN, SIZE, DURATION: This study uses population-based Australian clinical registry data comprising 9384 embryo transfer cycles that occurred between 2015 and 2021 for model development, with an external validation cohort of 1493 New Zealand embryo transfer cycles. PARTICIPANTS/MATERIALS, SETTING, METHODS: Three prediction models were compared that incorporated patient characteristics, but differed in whether they considered use of prior autologous treatment factors and current treatment parameters. We internally validated the models on Australian data using grouped cross-validation and reported several measures of model discrimination and calibration. Variable importance was measured through calculating the change in predictive performance that resulted from variable permutation. The best-performing model was externally validated on data from New Zealand. MAIN RESULTS AND THE ROLE OF CHANCE: The best-performing model had an internal validation AUC-ROC of 0.60 and Brier score of 0.20, and external validation AUC-ROC of 0.61 and Brier score of 0.23. While these results indicate ∼15% less discriminatory ability compared to models assessed on an autologous cohort from the same population the performance of the models was clearly statistically significantly better than random, demonstrated generalizability, and was well-calibrated to the population studied. The most important variables for predicting the chance of a live birth were the oocyte donor age, the number of prior oocyte recipient embryo transfer cycles, whether the transferred embryo was cleavage or blastocyst stage and oocyte recipient age. Of lesser importance were the oocyte-recipient parity, whether donor or partner sperm was used, the number of prior autologous embryo transfer cycles and the number of embryos transferred. LIMITATIONS, REASONS FOR CAUTION: The models had relatively weak discrimination suggesting further features need to be added to improve their predictive power. Variation in donor oocyte cohorts across countries due to differences such as whether anonymous and compensated donation are allowed may necessitate the models be recalibrated prior to application in non-Australian cohorts. WIDER IMPLICATIONS OF THE FINDINGS: These results confirm the well-established importance of oocyte age and ART treatment history as the key prognostic factors in predicting treatment outcomes. One of the developed models has been incorporated into a consumer-facing website (YourIVFSuccess.com.au/Estimator) to allow patients to obtain personalized estimates of their chance of success using donor oocytes. STUDY FUNDING/COMPETING INTEREST(S): This research was funded by the Australian government as part of the Medical Research Future Fund (MRFF) Emerging Priorities and Consumer Driven Research initiative: EPCD000007. L.R. declares personal consulting fees from Abbott and Merck, lecture fees from Abbott, receipt of an educational grant from Merck, past presidency of the Fertility Society of Australia & New Zealand and World Endometriosis Society and being a minor shareholder in Monash IVF Group (ASX:MVF). G.M.C. declares receipt of Australian government grant funding for the research study and the development and maintenance of the YourIVFSuccess website. O.F., J.N., and A.P. report no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Fitzgerald O, Newman J, Rombauts L, et al. Development of an IVF prediction model for donor oocytes: a retrospective analysis of 10 877 embryo transfers. Hum Reprod. 2024. PMID: 39173599. doi:10.1093/humrep/deae174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。